MLH1 and neoplasm: LB100 and anti-PD-1 co-treatment in multiple cancerous syngeneic mouse models resulted in MLH1 protein loss, greater microsatellite instability, and significantly smaller tumor volumes than those in control groups (P = 0.01), corresponding to increased tumor neoantigen expression.